ICER

News

ICER raps conduct of Lykos’ psychedelic trial for PTSD

The Institute for Clinical and Economic Review (ICER) typically focuses on the cost-effectiveness of new therapies, but in an unusual move has sharply criticised the desig

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

ICER backs sickle cell gene therapies at one-off cost of $2m

The influential Institute for Clinical and Economic Review (ICER) in the US has issued draft guidance suggesting that new gene therapies for sickle cell disease (SCD) from

News

Leqembi still too pricey, says ICER in updated review

Side effects create 'uncertainties' as to whether lecanemab's benefits exceed its risks.

News

x-ray image of human head with brain and electric pulses

ICER says lecanemab data in Alzheimer's "inconclusive"

One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<

Views & Analysis

Advanced therapies and the high-profile pricing dilemma

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in small

ICER raps conduct of Lykos’ psychedelic trial for PTSD

Acadia pulls trials of pimavanserin after schizophrenia fail

ICER backs sickle cell gene therapies at one-off cost of $2m

Leqembi still too pricey, says ICER in updated review

ICER says lecanemab data in Alzheimer's "inconclusive"

Advanced therapies and the high-profile pricing dilemma

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ICER

Editor's Picks